AI assistant
ARIKA RESOURCES LIMITED — Board/Management Information 2007
Aug 26, 2007
64420_rns_2007-08-26_d0f5e486-b591-4da5-8207-ca0c1dffe214.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [96 x 126] intentionally omitted <==
Announcement
Appointment of additional Company Secretary
27 August 2007,Sydney
Portland Orthopaedics Limited (ASX: PLD) advises the appointment of an additional Company Secretary. David Edwards, the Company’s current Company Secretary recently relocated to Western Australia with his family. He resigned as an employee of the company on May 11, 2007 but remains Company Secretary.
The Board of Directors are pleased to announce that joining David as Company Secretary is the interim Chief Financial Officer Mr James Wynn. James is a Chartered Accountant and has graduated from Sydney University with a Bachelor of Economics degree, the MGSM with a Masters in Management and is also a graduate of the Australian Institute of Company Directors. James is a Member of the Australian Institute of Management Consultants.
James Wynn has previously spent ten years in corporate advisory with Rothschild, BZW and KPMG Corporate Finance and most recently was Chief Financial Officer of Parnell Pharmaceuticals.
Enquiries:
David Sekel Portland Orthopaedics 0414 446 622
David Edwards Portland Orthopaedics 0410 343 667
Phone: + 61 2 9700 1533
Fax: + 61 2 9666 8544 Web: www.portland-orthopaedics.com Post: Unit 3, 44 McCauley St Matraville 2033 ABN: 92 082 839 992
About Portland Orthopaedics : Listed on the ASX in December 2005, Portland (ASX:PLD) is a developer and manufacturer of specialist hip and knee joint replacements. Portland’s first product, the DTC Hip, was conceived in 1991 as standard hip implants proved inadequate in cases with substantial bone loss especially where a hip implant had already been inserted. Portland’s first hip implant was trialled in 1997 and so far more than 1,800 implants have been sold, the majority in the US and Australia.
Portland has regulatory approval to sell a range of primary, revision and tumour hip replacement products in the US, Europe, Australia, New Zealand and Israel. The core technologies are all patented and future applications include shoulders, ankles and other joints.